Neuronal activity promotes high-grade glioma (HGG) growth. An important mechanism mediating this neural regulation of brain cancer is activity-dependent cleavage and secretion of the synaptic molecule and glioma mitogen neuroligin-3 (Nlgn3), but the therapeutic potential of targeting Nlgn3 in glioma remains to be defined. We demonstrate a striking dependence of HGG growth on microenvironmental Nlgn3 and determine a targetable mechanism of secretion.
PDGFRa::Cre ER driver mouse (Extended Data Fig. 6 ). Using the acute slice paradigm together 1 3 9
with inducible, conditional deletion of Nlgn3 from either neurons or from OPCs, we find that 1 4 0 both cells types contribute to activity-regulated Nlgn3 secretion, and notably OPCs are a major 1 4 1 source of secreted Nlgn3 (Fig.4e , f).
4 2
We previously demonstrated that NLGN3 exposure results in feed-forward glioma cell to the pool of secreted NLGN3 in the microenvironment. We find elevated levels of secreted exposed to recombinant NLGN3 or to control vehicle and then washed prior to CM collection. We find up-regulation of NLGN3 secretion from glioma cells following NLGN3 exposure To determine the enzyme responsible for the cleavage of Nlgn3, the amino acid sequence of the 2 1 2
We next tested the influence of ADAM10 inhibition on HGG growth in vivo. Brain a single 100 mg/kg intraperitoneal (i.p.) dose, drug levels in brain tissue were found to be ~2-4
μM, indicating sufficient blood-brain-barrier penetration (Extended Data Table 1 ). Given the 2 1 7
possible effects of ADAM10 inhibition on glioma self-renewal and therefore tumor initiation, pcGBM2-GFP-luc) cells were xenografted into the cortex or DIPG (SU-DIPGVI-GFP-luc or xenografting, mice were treated with either the ADAM10 inhibitor GI254023X (100 mg/kg) or 2 2 2 vehicle control 5 times/week over the course of 2 weeks and monitored using in vivo 2 2 3 bioluminescent imaging. GI254023X was well tolerated, with no apparent adverse events. The stagnation of glioma xenografts in the Nlgn3-deficient brain described above. Histological analyses revealed a reduced proliferation index in ADAM10 inhibitor-treated animals as assessed by the fraction of glioma cells co-expressing the proliferation marker Ki67 (Fig. 6g-h ).
9
Furthermore, we found that ADAM10 inhibition abrogates glioma cell secretion of neuroligin-3 The present study highlights a means to target the growth-promoting effects of neuronal Institutional Animal Care and Use Committee and performed in accordance with institutional
guidelines. Animals were housed according to standard guidelines with free access to food and
water in a 12-hour light/dark cycle.
9 2
For constitutive knockout studies, Nlgn3 KO mice (The Jackson Laboratory) were intercrossed
with NSG mice (NOD-SCID-IL2R gamma chain-deficient, The Jackson Laboratory) to produce the Nlgn3 KO;NSG genotype. All experiments were performed on male mice either hemizygous WT Nlgn3 or hemizygous null Nlgn3 littermates. For conditional knockout experiments, Nlgn3 fl/fl mice (a kind gift from Dr. Thomas Sudhof) or blinded investigator so that experimental groups contained an equivalent range of tumor sizes. growth. Statistical analysis between tumor burden in each group was assessed using Student's 3 0 9
two-tailed t-test (parametric data) or Mann Whitney test (non-parametric data). Based on the
variance of xenograft growth in control mice, we used at least 3 mice per genotype to give 80%
power to detect an effect size of 20% with at a significance level of 0.05. Orthotopic xenografting: A single-cell suspension from cultured neurospheres was prepared in
sterile PBS immediately prior to the xenograft procedure. Animals at p34-36 were anesthetized
with 1-4% isoflurane and placed in a stereotactic apparatus. The cranium was exposed via infusion, syringe needle was allowed to remain in place for a minimum of 2 minutes, then
manually withdrawn at a rate of 0.875 mm/minute to minimize backflow of the injected cell
suspension.
2 7
Perfusion and immunohistochemistry: Animals were anesthetized with intraperitoneal Avertin (1:300, Abcam), Mouse anti-human nuclei clone 235-1 (1:100; Millipore), or rabbit anti-Ki67
(1:500; Abcam), were diluted in 1% blocking solution (1% normal donkey serum in 0.3% Triton X-100 in TBS) and incubated overnight at 4°C. Sections were then rinsed three times in 1X TBS with the exception of SU-DIPG-XIX which is a H3.3K27M mutant tumor that was derived at the 3 4 7
time of autopsy from a male who was 2 years of age at diagnosis, was treated with radiotherapy routinely tested for mycoplasma.
All high-grade glioma cultures were generated as previously described 1 . In brief, tissue was grown in a defined, serum-free medium designated "Tumor Stem Media (TSM)", consisting of Biotech), human-EGF (20 ng/mL) (Shenandoah), human PDGF-AA (10 ng/mL) and PDGF-BB (10 ng/mL) (Shenandoah) and heparin (2 ng/mL) (Stem Cell Technologies).
Breast cancer brain metastasis line, PDX DF-BM354, was provided by the Zhao lab and 3 6 0 developed as previously described 12 .
3 6 1
Generation of conditioned media from acute cortical slices: Conditioned media was generated as weeks were briefly exposed to 4% isofluorane and immediately cervically dislocated and least one hour. After recovery, slices were then moved into fresh aCSF in a 24-well plate and
slices optogenetically stimulated using a blue-light LED to observe the effects of elevated performed in three biological replicates unless otherwise indicated.
EdU incorporation assay: 8-well chamber slides were coated with poly-L-lysine. Cells were then
seeded at 40,000 cells per well and exposed to aCSF, aCSF the relevant inhibitor (see below), or well. Cells were fixed after 24 hours using 4% paraformaldehyde in PBS and stained using the Click-iT EdU kit and protocol (Invitrogen). Proliferation index was then determined by quantifying percentage of EdU labeled cells using confocal microscopy at 200x magnification.
Group mean differences were otherwise assessed using one-way analysis of variance (one-way were performed in three biological replicates.
CellTiter-Glo assay of cell viability: To assess overall cell number, 5000 glioma cells were inhibitor. After 24, 48, or 72 hours, CellTiter-Glo reagent (Promega) was added at a 1:1 ratio.
Luminescence was measured after 10-minute incubation at room temperature to stabilize signal. All experiments were performed in three biological replicates. Aldrich); PF-00562271 at 5nM (FAK inhibitor; S2672; Selleck Chemicals). Analysis of NLGN3 secretion from glioma: For in vivo studies demonstrating NLGN3 secretion
from xenograft-bearing slices, mice were xenografted as above with SU-DIPGXIII or presence of absence of ADAM inhibitor. These experiments were performed in triplicate. for presence of cleaved NLGN3 using western blot analyses as described below. Experiments
were performed in three biological replicates. Spheroid invasion assay was performed as previously described 16 . a LIVE/DEAD staining kit (Thermo, cat. L10119). Live cells were sorted into 96 well plates.
2 5
Spheres were counted at 14 days. Cell density per well ranged from: 1, 10, 25, 50, 100, 250, 500, Neurosphere-forming capability was determined using the Extreme Limiting Dilution Analysis 4 3 0 (ELDA) web-based tool (http://bioinf.wehi.edu.au/software/elda/). blocked with 5% bovine serum albumin (BSA) in TBST for one hour. Anti-Neuroligin-3 4 3 9
(NovusBio; 1:300), Anti-phospho FAK pTyr861 (Thermo Fisher Scientific; 1:500), and anti- were purified over C18 STAGE tips (Rappsilber). Enriched peptides were subjected to secondary 4 6 7 digest with trypsin and second STAGE tip prior to LC-MS/MS analysis. Replicate injections of each sample were run non-sequentially for each enrichment. Peptides MS/MS spectra were evaluated using SEQUEST and the Core platform from Harvard for product ions. Enzyme specificity was limited to trypsin, with at least one LysC or tryptic (K- discovery rates, and filtered using a 5% FDR in the Linear Discriminant module of Core.
8 5
Peptides were also manually filtered using a -/+ 5ppm mass error range and reagent-specific in Progenesis or in the ion chromatogram files. Samples were processed and analyzed as previously described 16 with minor modifications as 4 9 4 indicated below:
RNA was extracted from Trizol-lysed cells and 1 µg of total RNA was used for each sample.
9 6
Polyadenylated RNA was selected using Ambion Dynabeads mRNA Purification Kit (Life
Technologies 61006) and fragmented with Fragmentation Buffer (Ambion, #AM8740). First
strand synthesis was performed using Random Hexamer Primers (Invitrogen, #48190-011) and
SuperScript II (Invitrogen, #18064-014). Second strand synthesis was performed using DNA Pol I (Invitrogen #18010-025) and RNA was removed using RNaseH (Invitrogen #18021-014). Genomics Facility.
0 4
Reads were mapped to hg19 annotation using Tophat2 (PMID: 23618408) (version 2.0.13) and 5 0 5
transcript expression was quantified against RefSeq gene annotations using featureCounts 47 .
0 6
Differential testing and log2 fold change calculation was performed using DESeq2 48 . Gene
Ontology analyses were performed using DAVID 49,50 . Pharmacokinetic studies: volume of bullet blender beads (Next Advance) and 3 volume of Milli-Q water were added.
LC-MS/MS analysis of GI254023X concentrations in tissues and serum.

1 5
Tissues were homogenized by a bullet blender (Next Advance) at 4°C according to
manufacturer's instruction. The neat stock solution of GI254023X was dissolved in DMSO at 5 5 1 7 mg/ml and further diluted in 50% methanol to prepare spiking solutions. For spiked standard
curve, 25 µl of GI254023X spiking solutions (0.5 -1000 ng/ml for brain samples and 1 -100
µg/ml for serum and kidney samples) was mixed with 25 µl of blank tissue homogenate or was added to the mixture and vortexed vigorously for 1 min followed by centrifugation at 3,000 QTRAP 4000 mass spectrometer (AB SCIEX) coupled to a Shimadzu UFLC system. LC 5 2 6
separation was carried out on a ZORBAX SB-Phenyl column (4.6 mm × 50 mm, 3.5 µm) 5 2 7
(Agilent) at room temperature. The analysis time was 3 min. The injection volume was 5-10 µl.
2 8
Isocratic elution was carried out with a mobile phase composed of 55% water and 45% 5 2 9
acetonitrile with 0.1% of formic acid and a flow rate of 0.5 ml/min. The mass spectrometer was (AB SCIEX). were fed with Co 60 dry granule food, with free access to reverse osmosis water. Eight time points were collected for each compound (0.25, 0.5, 1, 2, 4, 6, 8, and 24 h) , with an n = 3 for each time Lyser II to give a fine homogenate. Brain homogenate (50 µL) was treated with 250 µL with tolbutamide as an internal standard. Pharmacokinetics were analyzed using WinNonlin6.3
(non-compartmental model). Mouse drug treatment studies: For all drug studies, NSG mice were xenografted as above with before treatment, and again 7 days and 14 days later, using an IVIS imaging system (Xenogen)
under isoflurane anesthesia. Similar to above, tumor burden was assessed as fold change in total 5 6 8
flux from the beginning to end of treatment. All differences were statistically verified using
Students two-tailed t-test. Confocal imaging and quantification of cell proliferation: Cell quantification was performed by 5 7 2 a blinded investigator using live counting at 400x magnification using a Zeiss LSM700 scanning stereotactic coordinates for tumor xenograft, these sections are expected to include the tissue consecutive sections, the cingulum bundle was first identified as an anatomic landmark, and six (non-parametric data).
8 9
Statistical Analyses: Statistical tests were conducted using Prism (GraphPad) software unless 5 9 0 otherwise indicated. Gaussian distribution was confirmed by the Shapiro-Wilk normality test. For parametric data, unpaired, two-tailed Student's t-tests and one-way ANOVAs with Tukey post-hoc tests to further examine pairwise differences were used. For non-parametric data, Cre) cortical slices at baseline neuronal activity. Note that the Western blots in panels e and f 8 0 4
were run on the same gel. P values indicated on graphs; Student's two-tailed t-test. Data are 8 0 5
shown as mean+/-s.e.m. Thy1::ChR2 slices in the presence and absence of specific protease inhibitors as indicated. b,
Nlgn3 Western blot analyses of optogenetically stimulated Thy1::ChR2 cortical slice
homogenates +/-ADAM10 and MMP2/9 inhibitors. c, Proliferation indices of SU-pcGBM2 cells micrographs of SU-pcGBM2 cells (EdU, red; DAPI, blue) exposed to CM +/-ADAM10 treatment with vehicle (~1% DMSO) or NLGN3 (100 nM). The x-axis shows mean FPKM value Benjamini-Hochberg adjustment. Genes associated with each GO BP term shown in (c). Recombination rate of inducible Cre driver models 7 days after treatment with tamoxifen specific CamKIIa:CreER Cre driver, recombination efficiency was quantified as percent of
